Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
暂无分享,去创建一个
Jordi Giralt | K. Ang | P. Harari | D. Raben | D. Rosenthal | J. Giralt | Joyce F. Liu | J. Bonner | Paul M Harari | Joyce Liu | David I Rosenthal | David Raben | James A Bonner | D. Bell | Jeltje Schulten | Diana Bell | Kian K Ang | J. Schulten
[1] E. Vokes,et al. A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer. , 2015 .
[2] A. Cmelak,et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. , 2015, The Lancet. Oncology.
[3] A. Jimeno,et al. 986ORANDOMIZED PHASE II STUDY OF MEHD7945A (MEHD) VS CETUXIMAB (CET) IN >= 2ND-LINE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK (RMSCCHN) PROGRESSIVE ON/AFTER PLATINUM-BASED CHEMOTHERAPY (PTCT). , 2014, Annals of Oncology.
[4] A. Psyrri,et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] S. Faivre,et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. , 2013, The Lancet. Oncology.
[6] C. McConkey,et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region , 2013, Head & neck.
[7] R. Bhargava,et al. The role of human papillomavirus in nongenital cancers , 2013, CA: a cancer journal for clinicians.
[8] K. Ang,et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. El‐Naggar,et al. p16 expression as a surrogate marker for HPV‐related oropharyngeal carcinoma: A guide for interpretative relevance and consistency , 2012, Head & neck.
[10] Esther Kim,et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Fisher,et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] K. Ang,et al. Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.
[13] Jordi Giralt,et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.
[14] W. Westra,et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.
[15] Brian O'Sullivan,et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis , 2006, The Lancet.
[16] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[17] M. Mazumdar,et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil–cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck , 2004, Anti-cancer drugs.
[18] J. Ensley,et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Pignon,et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta analysis of chemotherapy on head and neck cancer , 2001 .
[20] P. Harari,et al. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] D. Sidransky,et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.
[22] J. Bourhis,et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.
[23] A. Huang,et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.
[24] S. Briggs,et al. Epidermal growth factor receptor-reactive monoclonal antibodies: xenograft antitumor activity alone and as drug immunoconjugates. , 1991, Cancer research.
[25] Ron Brookmeyer,et al. A Confidence Interval for the Median Survival Time , 1982 .